Taiga Nishihori

Oct 17, 2024 | nature.com | Catherine Lee |AKSHAY SHARMA |Taiga Nishihori |Tim Prestidge |Margaret MacMillan |Stephen Spellman | +1 more

AbstractBacterial bloodstream infections (BSI) can be a substantial contributor to complications of GVHD treatment. The aim of this study was to determine the risk for BSI from neutrophil engraftment through day 100 post transplant in patients with acute GVHD (AGVHD) based on organ involvement and severity. Patients (n = 4064) who underwent an allogeneic hematopoietic stem cell transplant (HCT) reported to the CIBMTR registry were analyzed.

Aug 8, 2024 | targetedonc.com | Taiga Nishihori

Taiga Nishihori, MD, senior member in the Blood & Marrow Transplant and Cellular Immunotherapy Department at Moffitt Cancer Center, discusses the findings from a single-center, retrospective study evaluating ciltacabtagene autoleucel (cilta-cel; Carvykti) given in the outpatient setting to patients with relapsed/refractory multiple myeloma, and the future directions for this research.

Jul 20, 2024 | targetedonc.com | Taiga Nishihori

Taiga Nishihori, MD, senior member in the Blood & Marrow Transplant and Cellular Immunotherapy Department at Moffitt Cancer Center, discusses a study in which investigators evaluated patients with relapsed and/or refractory (R/R) multiple myeloma who were hospitalized and treated with commercial ciltacabtagene autoleucel (cilta-cel; Carvykti) at Moffitt Cancer Center between May 2022 and May 2023.